Patents Examined by Lisa V. Cook
  • Patent number: 10947598
    Abstract: Provided is an in vitro method for determining the metabolic status of a lymphoma comprising a step of determining the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells, wherein a low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. Also provided is an in vitro method for predicting the responsiveness of a patient afflicted with a lymphoma to a treatment with a metabolic inhibitor selected from the group consisting of mitochondrial metabolic inhibitors and glutamine metabolism inhibitors comprising a step of determining the level of GAPDH expression in lymphoma cells obtained from said patient, wherein a low level of GAPDH expression is predictive of a response to a treatment with a metabolic inhibitor.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: March 16, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Université Côte d'Azur, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jean-Ehrland Ricci, Johanna Chiche, Catherine Thieblemont
  • Patent number: 10948498
    Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lorraine
    Inventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
  • Patent number: 10940181
    Abstract: Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: March 9, 2021
    Assignee: IMMUTEP S.A.S.
    Inventors: Frederic Triebel, Chrystelle Brignone
  • Patent number: 10934356
    Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 2, 2021
    Assignee: The Johns Hopkins University
    Inventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
  • Patent number: 10928398
    Abstract: The present invention relates to kits and methods for performing dual-staining immunohistochemistry (IHC) for the detection of specific cell populations in tissue samples containing heterogeneous populations of cells, which can be observed by a light microscope for co-localization of distinct pigments. The method includes providing a tissue sample comprising fixed cells; exposing the sample to first and second ligands that recognize different marker proteins found at the same cellular location, thereby forming a ligand-labeled sample; exposing the ligand-labeled sample to first and second labeling reagents, the first labeling reagent binding to the first ligand and the second labeling reagent binding to the second ligand, the first and second labeling reagents each forming distinct pigments; and identifying the number of cells that display only one particular pigment, or more than one pigment, by the different coloration of the cellular location labeled by the distinct pigment.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: February 23, 2021
    Assignee: CORNELL UNIVERSITY
    Inventor: Scott A. Ely
  • Patent number: 10900968
    Abstract: A method of prognosing and predicting breast cancer recurrence stratifies early stage ER+/PR+ and Her2? breast cancer patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an IHC based assay which assesses or measures expression of a combination of 5 biomarkers and by employing a histopathological analysis which assesses 3 clinical prognostic parameters.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: January 26, 2021
    Assignee: ONCOSTEM PTE. LTD.
    Inventors: Manjiri Bakre, Charusheila Ramkumar
  • Patent number: 10877034
    Abstract: The present invention relates to methods for predicting a risk of a subject for Type 1 diabetes (T1D) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: December 29, 2020
    Assignee: TURUN YLIOPISTO
    Inventors: Robert Moulder, Santosh Bhosale, David Goodlett, Harri Lähdesmäki, Olli Simell, Riitta Lahesmaa
  • Patent number: 10852307
    Abstract: The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, and to the prevention of these allergic diseases.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: December 1, 2020
    Assignees: National Jewish Health, Samsung Life Public Welfare Foundation
    Inventors: Donald Y. M. Leung, Byung Eui Kim, Jihyun Kim, Kangmo Ahn
  • Patent number: 10823741
    Abstract: A method for detecting a cardiac failure patient is provided. The method comprises (1) measuring a value of CKAP4 in a blood sample collected from a subject; (2) comparing the measured value of CKAP4 with a predetermined standard value; and (3) determining the subject as being a cardiac failure patient when the measured value of CKAP4 in the blood sample of the subject is lower than the predetermined standard value.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: November 3, 2020
    Inventor: Akira Matsumori
  • Patent number: 10822660
    Abstract: The present invention relates to a method for discrimination of p16.sup.INK4a overexpressing metaplasias from neoplastic or preneoplastic p16.sup.INK4a overexpressing lesions by determination of the level of high risk HPV encoded gene-products such as e.g. HPV E2 and/or HPV E7 molecules in biological samples in the course of cytological testing procedures. The method thus enables for reduction of false positive results in the p16.sup.INK4a based detection of anogenital lesions in cytological testing procedures.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: November 3, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Rudiger Ridder, Magnus Von Knebel Doeberitz, Peter Martin
  • Patent number: 10815526
    Abstract: Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. In particular, the invention relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining a sample from a pediatric patient having at least one indication of septic shock, then quantifying from the sample an amount of one or more of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: October 27, 2020
    Assignees: CHILDREN'S HOSPITAL MEDICAL CENTER, UNIVERSITY OF CINCINNATI
    Inventors: Christopher John Lindsell, Hector R. Wong
  • Patent number: 10793619
    Abstract: Provided are compositions and methods for preparing a cell suitable for producing a bispecific antibody. A plurality of eukaryotic cells are incubated with an agent under conditions to allow the cells to arrest at G1/S phase. The agent is then removed from the cells and the cells are transfected with a first vector comprising a sequence encoding a first monovalent antigen-binding unit having specificity to a first antigen and a second vector comprising a sequence encoding a second monovalent antigen-binding unit having specificity to a second antigen. A cell is identified from the plurality of cells that expresses both the first and the second antigen-binding units.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: October 6, 2020
    Assignee: Wuhan YZY Biopharma Co., Ltd.
    Inventors: Pengfei Zhou, Jing Zhang, Rui Wang, Xiang Zhou, Xiaoyan Liu, Lingli Hu, Sisi Fu, Hui Zhong
  • Patent number: 10787517
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 29, 2020
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • Patent number: 10787516
    Abstract: Antibodies that bind to AXL protein and variants thereof are described herein. AXL exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the MAbs of the invention provide a diagnostic composition for the treatment and management of cancer.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 29, 2020
    Assignee: AGENSYS, INC.
    Inventor: Karen Jane Meyrick Morrison
  • Patent number: 10782301
    Abstract: The present invention relates to pancreatic cancers and the use of biomarkers in biological samples for the diagnosis of such conditions, in particular pancreatic ductal adenocarcinoma. The biomarker panel comprises LYVE1, REG1 and TFF1. Methods of treatment arc also provided, as well as kits useful in the diagnosis and treatment of pancreatic ductal adenocarcinoma. The present invention is particularly useful in detecting early-stage PDAC.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 22, 2020
    Assignee: Queen Mary University of London
    Inventors: Tatjana Crnogorac-Jurcevic, Tomasz Radon
  • Patent number: 10768079
    Abstract: A microscope slide staining system has a chamber, a plurality of slide support elements, a plurality of spreading devices positionable in association with microscope slides supported on the slide support elements so the spreading devices define a gap between the spreading device and the microscope slide and so the spreading device and the microscope slide are movable relative to one another to spread at least one reagent on the microscope slide independent of the other spreading devices and microscope slides.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: September 8, 2020
    Inventor: Lee H. Angros
  • Patent number: 10744116
    Abstract: Methods of predicting or detecting sensitivity to therapeutic effects of anti-PD-1 therapy in a patient suffering from melanoma, as well as for selecting somatic mutanomes and transcriptomes of melanoma biopsies. A tumor sample obtained from the patient is assayed for a measure of anti-PD-1 therapy sensitivity via, for example, whole transcriptome sequencing, antibody based protein quantifications, mass spectrometry based protein quantification, targeted mRNA sequencing, real-time RT-PCR, Sanger sequencing, targeted sequencing and/or whole exome/genome sequencing. Samples are selected that exhibit a higher first enrichment similarity score and/or a lower second enrichment similarity score, and/or at least one measure of sensitivity. A patient whose sample was selected herein as a candidate for anti-PD-1 therapy is thereby identified. The method of the invention can further comprise treating the patient with anti-PD-1 therapy, optionally in conjunction with combinatorial therapy.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: August 18, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Roger S. Lo, Willy Hugo, Antoni Ribas, Jesse Zaretsky
  • Patent number: 10732187
    Abstract: Described herein are compositions and methods for the detection of inner ear disorders such as balance disorders and hearing disorders resulting from acoustic injury, exposure to ototoxins, head trauma or viral illness. Specifically, otolin-1 and prestin have been verified as inner-ear specific biomarkers suitable for the detection of inner ear disorders.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: August 4, 2020
    Assignee: The University of Connecticut
    Inventor: Kourosh Parham
  • Patent number: 10732182
    Abstract: The present invention relates to methods of determining cancer cell sensitivity to treatment by using antibodies that specifically bind to and detect the presence of a Bcl-2 heterodimer protein, or a caspase and an inhibitor of caspase-IAP heterodimer protein in the cell. The methods provide a predictive tool to identify patients likely to respond to drugs that perturb heterodimer binding and induce apoptosis in a cancer cell. The invention also provides a method of predicting therapeutic efficacy in a cancer patient.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: August 4, 2020
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventor: Michael H. Cardone
  • Patent number: 10725029
    Abstract: A kit for in vitro or ex vivo measurement of sCD127 expression in a biological sample, the kit including: specific tools or reagents allowing measurement of sCD127 expression in said biological sample; and a positive standard sample which is a sample calibrated to contain an amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known to have developed a nosocomial infection, and/or a negative standard sample which is a sample calibrated to contain the amount of sCD127 which corresponds to the mean amount measured in a pool of samples from patients who are known not to have developed a nosocomial infection.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: July 28, 2020
    Assignees: HOSPICES CIVILS DE LYON, BIOMERIEUX
    Inventors: Alain Lepape, Fabienne Venet, Astrid Villars, Guillaume Monneret